BOLANDCELL ANNOUNCES FAVOURABLE REJUVENATION AND DERMAL REGENERATION WITH CULTURED HUMAN FIBROBLASTS, COMPARED TO PRP
Cape Town, 4 June 2008, 09:30. BOLANDCELL announced that cultured autologous human fibroblasts render superior facial skin rejuvenation results compared to platelet rich plasma (PRP or A-PRP), more specifically in the nasolabial region and upper lip. In the interim follow-up period, cultured human fibroblasts have rendered good dermal regeneration and autologous cellular regeneration ( ACR). This is the first anecdotal report showing showing results of cultured fibroblasts compared to PRP in aesthetic, beauty and cosmetic medicine in the treatment of facial rhytids. And is the first documentation by the specialist biotechnology unit in Cape Town, supported by advanced skin analysis after cell therapy with platelets or fibroblasts.
This report follows shortly after the announcement of Isolagen™ , a biotechnology company in the United States, on completion phase 111 trials and upgraded phase 11 studies for amelioration of facial rhytids with cultured autologous human fibroblasts ( patented “ Isolagen Process”).
This is the first small open-ended study that reports anecdotal, comparative results backed by objective measurements and advanced skin analysis ( both morphologically and functional) following attempts to ameliorate facial wrinkles ( rhytids) and reverse the aging process by cosmetic manipulation either by the “ Isolagen Process” or platelet rich plasma ( A-PRP or C-PRP) in persons with grade 2-5 type skin ( with chronological or solar aged face). Both forms of treatment are referred to as cell therapy. The “Isolagen Process” is the clinical application of cultured autologous human fibroblasts, and PRP utilizes the application of activated human platelets. During the “ Isolagen Process” the cultured fibroblasts ( cultured over a period of 4-8 weeks) are injected into the dermis by a course of 3-4 injections over a 6 week period. The newly transplanted fibroblasts, rejuvenate the adjacent aging dermis by forming collagen and elastin and other components of the ECM. PRP injected into the dermis and hypodermis for aesthetic purposes, stimulates resident fibroblasts and other mesenchymal cells by biostimulation, to enhance collagen deposition and activation of the ECM.
The nasolabial and upper lip rejuvenation are far superior at the 2-year mark in persons undergoing facial rhytid amelioration by cultured fibroblasts. Cell expansion was performed in Cape Town by a patented biotechnology process ( 2006\ 03057: PTC /EP 2007/058695). For aesthetic rejuvenation by PRP, a sample of venous blood was used after harvesting, centrifugation and activation. A-PRP, is exclusively distributed by Omnimed ( PTY) , Ltd, in Randburg, Gauteng, and is an excellent and safe alternative ( because the patients own plasma is used), if culture facilities are not available. Much the same as seen after IPL and laser treatment, the biological facial regeneration route is associated with variable results, for which there are many causes.
SKIN ANALYSIS DATA AT 2-YEARS AFTER AUTOLOGOUS CULTURED HUMAN FIBROBLAST CELL REPLACEMENT FOR DERMAL REGENERATION AND AMELIORATION OF NASOLABIAL AND UPPER LIP RHYTIDS
MICRO RELIEF EVALUATION OF THE SKIN SURFACE AFTER FIBROBLAST CELL THERAPY: CLINICAL IN VIVO STUDIES
- Roughness average :19.53 GL
- Max profile valley depth : 48.77 GL
- Max profile peak height: 99.17 GL
- Peak density: 9.88 GL
- Mean spacing of irregularities: 54.75 GL
- Anisotrophy index 18.34%
SKIN PHYSIOLOGY OUTCOMES AFTER FIBROBLAST CELL THERAPY: CLINICAL IN VIVO STUDIES
- Sebum density: 15.17 microgram per square centimetre ( lip surface 25.93 squared mm).
- TEWL: 7.2 g.h.m
- Hydration: 54%
- Temperature: 33.7 centigrade.
- Pigmentation profile: normal
CONCLUSIONS: Interim and short-term results show that cultured autologous human fibroblasts, render superior facial rejuvenation capability than A-PRP, probably because the concentrated cultured cells are quickly engrafted, deposit more collagen , and because millions of cells are engrafted. PRP, on the other hand has to stimulate single resident and senescent fibroblasts ( small numbers of cells) and therefore results may be subtle and modest, requiring follow-up treatment at 6 monthly intervals and supported by revitalizing cosmetic creams. Not all aesthetic practitioners have the advanced cell technology and expertise of BOLANDCELL, in which case A-PRP is a second best option for the biological rejuvenation of the face by cell therapy.
- Du Toit DF et al. Biotechnological anti-aging cell-therapy treatment of facial wrinkles with cultured human fibroblasts. The Specialist Forum.5:38-46, 2005.
- Du Toit DF et al. Soft and hard-tissue augmentation with platelet rich plasma: Tissue culture dynamics, regeneration and molecular biology perspective. International J of Shoulder Surgery 1:64-73, 2007 ( see www.internationalshoulderjournal.org) .
- Boss WK, et al. Clinics in Plastic Surgery, 27:613-626, 2000.
- Boss WK, et al. Ann Plastic Surg 44:536-542,2000.
Posted 4 June 2008
Figure 1: Skin photography, left profile: Upper lip and nasolabial fold two years after treatment with autologous cultured human fibroblasts.
Figure 2: Skin analysis .Micro-relief of the upper lip showing eradication and amelioration of rhytids , 2 years after cosmetic treatment with cultured human fibroblasts ( patented cell laboratory technology:2006/03057:PTC/EP 2007/058695).
Figure 3: Skin Analysis: Micro-relief of the nasiolabial fold showing good tone and texture, 2 years after beauty treatment with autologous cultured human fibroblasts.
Figure 4: Photograph of the left profile and perioral region , showing minimal skin rejuvenation retention, 12 months after A-PRP treatment.
Figure 5. Photograph showing an excellent response and complexion, after A-PRP facial rejuvenation in the short-term ( permission given to publish)
Figure 6: Upper lip. Autologous cultured human fibroblasts were used for " rescue skin re-surfacing" after deep laser burn and de-pigmentation. Note good skin texture after dermal regeneration ( ACR: autologous cellular regeneration ) by cultured fibroblast cell-therapy. Patented biotech and cell engineering: 2006/03057; PTC /EP 2007/058695.